Johnson & Johnson vs NovoCure Limited — Stock Comparison
Q·Score Breakdown
7.1
Bullish
Overall
5.4
Bearish
Quality
Health
Growth
Valuation
Sentiment
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
NVCR
Healthy balance sheet and financial position.
⚠ currently unprofitable (-26% margin).
Analyst Consensus
BUY
Target $252.42 (+11.1%)
24 analysts
BUY
Target $25.21 (+51.7%)
7 analysts
Fundamentals
JNJ
NVCR
26.3×
Trailing P/E
—
17.9×
Forward P/E
-14.3×
21.8%
Profit Margin
-25.7%
68.0%
Gross Margin
75.4%
26.4%
ROE
-50.0%
9.9%
Revenue Growth
12.3%
-52.9%
Earnings Growth
—
0.33
Beta
0.82
—
Price / Book
—
$546.9B
Market Cap
$1.9B
$146 – $252
52-Week Range
$10 – $20
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →